US 9592207
Intranasal administration of ketamine to treat depression
granted A61KA61K31/135A61K31/137
Quick answer
US patent 9592207 (Intranasal administration of ketamine to treat depression) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/135, A61K31/137, A61K45/06, A61K9/0019